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Summary
 
Signal transducers and activators of transcription 6 (STAT6) is essential for interleukin 4–medi-
ated responses, including class switching to IgE and induction of type 2 T helper cells. To in-
vestigate the role of STAT6 in allergic asthma in vivo, we developed a murine model of aller-
gen-induced airway inflammation. Repeated exposure of actively immunized C57BL/6 mice
to ovalbumin (OVA) aerosol increased the level of serum IgE, the number of eosinophils in
bronchoalveolar lavage (BAL) fluid, and airway reactivity. Histological analysis revealed peri-
bronchial inflammation with pulmonary eosinophilia in OVA-treated mice. In STAT6-defi-
cient (STAT6
 
2/2
 
) C57BL/6 mice treated in the same fashion, there were no eosinophilia in
BAL and significantly less peribronchial inflammation than in wild-type mice. Moreover
STAT6
 
2/2
 
 mice had much less airway reactivity than wild-type mice. These findings suggest
that STAT6 plays a crucial role in the pathogenesis of allergen-induced airway inflammation.
 
A
 
topic bronchial asthma is characterized by an increased
serum IgE level and an eosinophilic inflammation of
airway, which are accompanied by increased airway reac-
tivity (1–6). The cytokine IL-4 has pleiotropic effects and
appears to play a key role in the pathogenesis of atopic dis-
eases (7, 8). IL-4–deficient (IL-4
 
2/2
 
) mice fail to develop
both increase in the level of IgE in serum (9–12) and eosin-
ophil recruitment into airways (11, 12). Moreover, the air-
way hyperreactivity normally resulting from allergen chal-
lenge is abolished in IL-4
 
2/2
 
 mice (12) and mice treated
with anti–IL-4 antibody (13). These data show that IL-4 is
a central mediator in the pathogenesis of allergic asthma.
Signal transducers and activators of transcription (STAT)
proteins are family of transcription factors that mediate
many cytokine-induced responses (14). STAT6 is tyrosine
phosphorylated and activated in response to IL-4 (15, 16).
Similar to IL-4
 
2/2
 
 mice (9, 10), STAT6-deficient (STAT6
 
2/2
 
)
mice also abrogate IL-4–mediated functions including Th2
differentiation, expression of cell surface markers, and Ig
class switching to IgE (17–19). These findings demonstrate
that STAT6 is required for IL-4–specific functions, despite
the existence of multiple signaling pathways activated by
IL-4 (20, 21). However, it is still unclear whether a
STAT6-mediated signal is also in the pathogenesis of both
the peribronchial inflammation and the airway hyperreac-
tivity.
In this study, we examined the roles played by STAT6 in
a murine model of allergen-induced airway inflammation.
Our findings show that STAT6 may play a critical role in
the development of the pathophysiology of allergic asthma.
 
Materials and Methods
 
Animals.
 
C57/BL6 mice with targeted disruption of the gene
encoding STAT6 (STAT6
 
2/2
 
 mice) were generated in the De-
partment of Biochemistry, Hyogo College of Medicine (Hyogo,
Japan), as previously reported (17), and inbred in Experimental
Technology Research Center, Daiichi Pharmaceutical Co., Ltd.
(Tokyo, Japan). Age-matched C57/BL6 female mice were pur-
chased from SLC (Shizuoka, Japan). All animals were housed un-
der specific pathogen-free conditions, and had free access to com-
mercial diet and water.
 
Immunization and Exposure of Mice.
 
On the first day of the ex-
periment (day 0) and day 12, 5- or 6-wk-old female mice were
actively immunized by intraperitoneal injection of 50 
 
m
 
g of OVA
(Sigma Chemical Co., St. Louis, MO), adsorbed to 1 mg of alum
(Kyowa Kagaku, Kagawa, Japan) in 0.9% sterile saline. On day
23, mice were exposed to an aerosol of OVA in 0.9% sterile sa-
line for 30 min three times at 1-h intervals, and then every second
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day thereafter, for 8 d. The aerosol was generated with an ultra-
sonic nebulizer (NE-U12; Omron, Mie, Japan) driven by a plas-
tic filling box (length: 21.5 cm; width: 28.5 cm; height: 21.5 cm).
According to the specifications supplied by the manufacturer, the
output of the nebulizer is 0.5 ml/min, and the particles produced
have a mean diameter of 3.5 
 
m
 
m. The concentration of OVA in
the nebulizer was 10 mg/ml. 24 h after the last aerosol exposure,
the mice were anesthetized by intraperitoneal injection of pento-
barbital 80 mg/kg body weight (Tokyo Kasei, Tokyo, Japan) and
used for the following experiments.
 
Measurement of Serum Concentrations of IgE and IgM.
 
Blood was
drawn from the sinus cavernosus, and serum was obtained by
centrifugation at 1,500 
 
g
 
 for 10 min. Serum IgE level was deter-
mined with a commercial ELISA kit (Yamasa, Chiba, Japan).
Concentrations of IgM were determined by ELISA using goat
anti–mouse IgM (Southern Biochemistry Assoc., Birmingham,
AL) as capture antibody and goat anti–mouse IgM labeled with
biotin (Southern Biochemistry Assoc.) as detection antibody (17).
 
Bronchoalveolar Lavage.
 
The trachea was cannulated and the
airway lumina were washed twice with 0.5 ml of phosphate-buf-
fered saline (free of ionized calcium and magnesium) supple-
mented with 0.05 mM sodium EDTA (Sigma Chemical Co.) and
0.1% bovine serum albumin (Sigma Chemical Co.). The bron-
choalveolar lavage (BAL) fluid was immediately centrifuged (10
min, 4
 
8
 
C, 700 
 
g
 
). The BAL cells were resuspended in 0.2 ml of
rat serum and counted using a hemocytometer.
For differential cell counts, 2–4 
 
3 
 
10
 
3
 
 cells were spun onto
glass slides (Cytospin2; Cytospin, Shandon, UK), air dried, fixed
with ethanol, and stained with Giemsa solution. The number of
eosinophils, neutrophils, and macrophages/monocytes in 200 cells
were counted based on morphology and staining characteristics.
 
Lung Histology.
 
The lungs were resected, fixed in 10% phos-
phate-buffered formalin, embedded into paraffin, sectioned,
stained with hematoxylin-eosin solution, and examined by light
microscopy for histologic changes.
 
Measurement of Airway Hyperreactivity.
 
The trachea was can-
nulated and connected to a rodent ventilator (683; Harvard Ap-
paratus, South Natick, MA) with an in-line pressure transducer
(DP45-28; Validyne Engineering Corp., Northridge, CA) that
was coupled to a pulmonary mechanics analyzer (6; Buxco Elec-
tronics, Inc., Sharon, CT). Flows were determined by measuring
the differential pressure (DP45-14; Validyne Engineering Corp.)
across six layers of 400-mesh wire cloth covering a 1.3-cm hole
in a plethysmograph box (Plyan-M; Buxco Electronics, Inc.).
Mice were placed in the plethysmograph box and were then ven-
tilated at 120 strokes/min with a stroke volume of 0.3 ml after
neuromuscular blockade with 10 mg/kg succinylcholine (Tokyo
Kasei). After establishing a stable baseline of lung resistance (RL),
acetylcholine (Ach; Daiichi Pharmaceutical Co., Ltd., Tokyo, Ja-
pan) was cumulatively administered (31.5–1,000 
 
m
 
g/kg) via the
tail vein, and changes in RL were monitored.
 
Statistical Analysis.
 
All results are expressed as the mean 
 
6
 
SD.
Lung resistances in various groups were compared with a Dun-
nett’s test.
 
Results
 
No Elevation of Serum IgE in STAT6
 
2
 
/
 
2
 
 Mice.
 
C57BL/6
wild-type and STAT6
 
2/2
 
 mice immunized with OVA
were treated with aerosol of OVA. At the 24-h time point
after OVA challenge, mice were bled, and serum concen-
tration of Ig was measured by ELISA. C57BL/6 wild-type
mice displayed the expected increase in IgE concentration
after the treatment of OVA (Fig. 1 
 
a
 
). In contrast, the IgE
level was below 10 ng/ml in OVA-challenged STAT6
 
2/2
 
mice of C57BL/6 background. Serum concentration of
IgM was equally increased after OVA challenge in both
wild-type and STAT6
 
2/2
 
 mice, indicating that both mice
were sensitized with OVA (Fig. 1 
 
b
 
). Thus, STAT6
 
2/2
 
mice displayed no IgE response to OVA challenge.
 
No Eosinophilia in BAL Fluid of STAT6
 
2/2
 
 Mice.
 
To de-
termine whether STAT6 deficiency influences airway eosin-
ophilia, we analyzed the cells in BAL fluid 24 h later than the
last exposure to OVA aerosol (Fig. 2). In actively immunized
wild-type mice, the total cell number of BAL cells was dra-
matically increased after repeated exposure to OVA. Cell
Figure 1. Changes in serum concentrations of IgE and IgM induced by
OVA treatment. The columns represent the concentration of serum IgE
(a) and IgM (b) in wild-type and STAT62/2 mice after treatment with
(OVA) or without (Control) OVA. Results shown are from a single exper-
iment representative of three separate experiments. N.D., not detectable
(,10 ng/ml).
Figure 2. Effect of STAT6 deficiency on total BAL cell number and
cellular distribution of BAL fluid. BAL fluid was obtained from wild-type
and STAT62/2 mice after treatment with (OVA) or without (Control)
OVA. The columns represent the absolute numbers of total BAL cells,
eosinophils, neutrophils, macrophages, and other cells (mostly lympho-
cytes) per animal. Results shown are from a single experiment representa-
tive of three separate experiments. 
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differentiation analysis revealed the marked elevation of eosin-
ophil  population and slight increase in macrophages and
neutrophils in wild-type mice. In contrast, the total cell num-
ber of BAL cells was not increased after OVA exposure in
STAT6
 
2/2
 
 mice. Furthermore, eosinophils were scarcely de-
tected in BAL fluid of STAT6
 
2/2
 
 mice, even after OVA ex-
posure, demonstrating that STAT6
 
2/2
 
 mice exhibited no eo-
sinophilia in the airway, even after aerosolization with OVA.
 
No Inflammatory Response of Lungs in STAT6
 
2/2
 
 Mice.
 
In wild-type mice, exposure to OVA induced patchy in-
flammatory infiltrates in the lungs (Fig. 3 
 
A
 
). These infil-
trates were mainly located around the small bronchi, bron-
chioles, and blood vessels. Most of peribronchial inflammatory
cells consisted of lymphocytes and eosinophils. In contrast,
any inflammatory changes, including infiltration of eosino-
phils, were not observed in the lungs of STAT6
 
2/2
 
 mice af-
ter aerosolization with OVA (Fig. 3 
 
B
 
). Examination of the
lungs taken from OVA-treated STAT6
 
2/2
 
 mice revealed
normal lung histology similar to that in the lungs from un-
treated wild-type mice (Fig. 3 
 
C
 
). Thus, STAT6
 
2/2
 
 mice
displayed no inflammatory responses to OVA.
 
No Increased Airway Reactivity in STAT6
 
2/2
 
 Mice.
 
Mice im-
munized and subsequently aerosolized with OVA were an-
alyzed for airway reactivity after intravenous administration
of Ach (Fig. 4). In wild-type mice, OVA treatment signifi-
cantly increased the airway response to Ach, as compared
with untreated mice. However, the airway response to Ach
in OVA-treated STAT6
 
2/2
 
 mice was same as that in non-
treated STAT6
 
2/2
 
 and wild-type mice, demonstrating that
STAT6
 
2/2
 
 mice did not exhibit airway hyperreactivity af-
ter OVA sensitization.
Figure 3. Microscopic examination of lung tissues from wild-type and
STAT62/2 mice. Lung preparations from both wild-type and STAT62/2
mice treated with or without OVA were stained with hematoxylin-eosin.
Photomicrographs of these preparations were evaluated infiltration of
eosinophils and other lymphocytes in bronchial mucosa and perivascular
sheaths in lung. Noticeable cell accumulation of eosinophils appeared in
lungs from OVA-treated wild-type mice (A). In contrast, the inflamma-
tory cells were not shown in lungs from OVA-treated STAT62/2 mice
(B). The lungs taken from untreated wild-type mice represent normal
lung histology (C). Original magnification: 200. Figure 4. Effect of STAT6 deficiency on airway reactivity in OVA-
treated mice. Airway reactivity assessed by measurement of RL after in-
travenous Ach challenge in wild-type mice (circles) and STAT62/2 mice
(squares) treated with (closed symbols) or without (open symbols) OVA. Only
in wild-type mice, OVA treatment significantly increased airway reactiv-
ity compared with that in the untreated group (*P ,0.05). Results shown
are from a single experiment representative of three separate experiments. 
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Discussion
 
In this study, we demonstrate that pulmonary eosino-
philia, airway hyperreactivity, and lung damage usually
seen in mice immunized and challenged with antigen are
not observed in STAT6
 
2/2
 
 mice, suggesting that STAT6
activation plays an essential role in the pathogenesis of al-
lergic airway inflammation.
Bronchial asthma is a chronic airway disease with revers-
ible airway obstruction and airway inflammation. The
pathophysiological changes in asthma are characterized by
increased serum IgE level, eosinophil infiltration around
airways, bronchial mucosal injury, and airway hyperreac-
tivity (1–6). This pathophysiologic process of asthma is
thought to involve T helper cells with a Th2 cytokine phe-
notype. It has been reported that depletion of cluster of dif-
ferentiation (CD)4-positive lymphocytes prevents antigen-
induced airway reactivity and recruitment of eosinophils to
the airways (22). Bronchoalveolar lymphocytes and T cell
clones from airway mucosa with allergic respiratory disor-
ders synthesized and released IL-3, -4, -5, and GM-CSF,
indicating predominant differentiation of Th2 (23, 24).
Moreover, either IL-4 (12) or -5 (25) deficiency abolishes
airway hyperreactivity in mouse asthma models. Thus,
there is no doubt that IL-4 and -5 are key cytokines partic-
ipating in the various aspects of manifestations of asthma.
However, there are apparently discrepant reports on
their relative importance in airway hyperreactivity. Corry
et al. showed that neutralization of IL-4 using monoclonal
antibodies abrogated airway hyperreactivity but had little
effect on the influx of eosinophils, and that administration
of anti–IL-5 antibodies suppressed eosinophil recruitment
but had no effect on the subsequent airway response (13).
These data are similar to what was found in another report
in which bronchial responses to carbachol and serotonin
were substantially less in IL-4
 
2/2
 
 mice than in wild-type
mice (12), implicating IL-4 as the key cytokine and indicat-
ing that airway hyperreactivity can occur independently of
IL-5 and recruitment of eosinophils. In contrast, Foster et
al. provide equally convincing evidence that IL-5 is the
critical cytokine (25). They showed that eosinophilia, lung
damage, and airway hyperreactivity were abolished in IL-
5–deficient mice, and that reconstitution of IL-5 produc-
tion with recombinant vaccinia viruses completely restored
aeroallergen-induced eosinophilia and airway dysfunction.
Drazen et al. discussed two conflicting studies and specu-
lated that there are two distinct mechanisms for induction
of airway hyperreactivity, that is, IgE-stimulated activation
of mast cells that occurred in the model used by Corry et al.
and eosinophil-dependent pathway demonstrated in the
experiment by Foster et al. (26). Recently, Foster et al.
published a report showing that the recruitment of eosino-
phils to airways was not abolished or the characteristic air-
way damage and hyperreactivity were not attenuated in IL-
4
 
2/2
 
 mice (27). Moreover, they showed that treatment of
IL-4
 
2/2
 
 mice with anti–IL-5 antibodies before aeroallergen
challenge abolished blood and airway eosinophilia, lung
damage, and airway hyperreactivity. These results indicate
that IL-4 is not essential for the development of IL-5–pro-
ducing CD4-positive T cells or for the induction of eosino-
philic inflammation, airway damage, and hyperreactivity. This
finding contrasts with our present finding that STAT6
 
2/2
 
mice did not develop airway eosinophilia, lung damage, or
airway hyperreactivity.
Although STAT6 is clearly shown to be essential for IL-4
signaling, IL-4 is not the only cytokine that activates
STAT6. It has been reported that IL-13 also activates
STAT6 (28). Moreover, we have demonstrated that IL-13
signaling is completely abolished in STAT6
 
2/2
 
 mice (29).
IL-4 and -13 are related cytokines with many common bi-
ological properties (30). Overlapping biological properties
of IL-4 and -13 is now explained by the sharing of IL-4 re-
ceptor 
 
a
 
 chain as a common receptor component between
two cytokines (30). The IL-13 signaling pathway appears
to be an alternative pathway for IL-4 signaling in humans
(31–33). In patients with chronic allergic disease, repeated
stimulation of allergen-specific memory CD4 T cells ap-
pears to induce IgE production largely via IL-13 (34).
More importantly, like IL-4, IL-13 has the capacity to
make naive T cells differentiate into Th2s (19). Besides IL-4
and -13, STAT6 is activated through a leptin receptor (35),
surface Ig (36), CD40 (36), or may be activated through as
yet unknown receptors. Some of these signalings may also
participate in Th2 response. Although IL-4 plays a central
role in the differentiation of Th0s into Th2s, there is the
possibility that factors other than IL-4 mediate Th2 differ-
entiation in the absence of IL-4. Indeed, the residual Th2
response has been clearly observed in IL-4
 
2/2
 
 mice (37), in
contrast to the almost complete abolishment of Th2 re-
sponse in STAT6
 
2/2
 
 mice (17–19). This may explain the
marked difference in the morphological and functional
changes of the airways in response to aeroallergen challenge
between IL-4
 
2/2
 
 mice and STAT6
 
2/2
 
 mice.
In conclusion, this study demonstrates the critical role
for STAT6 in the development of murine aeroallergen-
induced airway inflammation, and suggests that blocking
the action of STAT6 may be a therapeutic approach worth
testing in the treatment of asthma.
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